Understand the source comparison
Comparison Table: Consent Requirements Across Peptide Research Phases
The regulatory intensity of peptide research ethics human studies consent escalates across trial phases. Here's how consent depth scales from preclinical to post-market. Phase I (First-in-Human) Safety, pharmacokinetics, maximum tolerated dose Must disclose al
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The regulatory intensity of peptide research ethics human studies consent escalates across trial phases. Here's how consent depth scales from preclinical to post-market.
- Phase I (First-in-Human)
- Safety, pharmacokinetics, maximum tolerated dose
- Must disclose all theoretical risks based on receptor biology; acknowledge data gaps in human safety; quantify known risks from animal models
- Must explicitly state no therapeutic benefit expected; participation is for scientific knowledge only
- Full board review required; annual continuing review
- Highest consent burden. Participants assume maximum unknown risk for zero personal benefit; comprehension verification mandatory
- Phase II (Proof-of-Concept)
- Preliminary efficacy, dose-response relationship, adverse event profiling
- Must quantify adverse event rates from Phase I; disclose preliminary efficacy signals without overstating benefit; explain placebo group assignment
- May state potential for therapeutic benefit if efficacy signals observed in Phase I; must clarify benefit is not guaranteed
- Full board review or expedited review depending on risk classification; semiannual continuing review
- Risk-benefit disclosure becomes more nuanced. Consent must balance hope with realistic probability of placebo assignment
- Phase III (Confirmatory Efficacy)
- Definitive efficacy vs standard of care or placebo; long-term safety monitoring
- Must compare risks and benefits to standard treatment options; disclose serious adverse events from prior phases; quantify dropout rates
- May describe expected therapeutic benefit with confidence intervals from Phase II data; must clarify study is still investigating safety
- Full board or expedited review; annual continuing review
- Consent resembles clinical decision-making. Participants weigh investigational peptide against existing treatments; equipoise must be maintained
- Post-Market / Phase IV
- Long-term safety surveillance, rare adverse event detection, real-world effectiveness
- Must disclose known serious adverse events from FDA label; explain difference between controlled trial conditions and real-world use
- Therapeutic benefit established by FDA approval; consent focuses on monitoring and data contribution
- Expedited review common; registry studies may qualify for waiver of informed consent under specific conditions
- Consent transitions from risk assumption to data contribution. Participants are receiving approved therapy while contributing to safety surveillance